PubMed Health⌕ Search

PubMed · 8644506

Copolymer adjuvants.

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R N Brey. 1995. Copolymer adjuvants.. https://doi.org/10.1007/978-1-4615-1891-4_4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part I: composition and structure.

Aluminium phosphate adjuvant was precipitated under constant pH conditions in an effort to characterize materials formed at defined precipitation conditions. A reaction vessel was designed to provide a continuous steady-state process. An aqueous solution containing aluminium chloride and sodium dihydrogen phosphate was pumped into the reaction vessel at a constant rate. A second pump infused a sodium hydroxide solution at the rate required to maintain the desired pH. Precipitations were performed between pH 3.0 and 7.5, at intervals of pH 0.5. The adjuvants were characterized using 27Al NMR, FTIR, Raman and X-ray diffraction methods along with elemental analysis. The results of this study indicate that a continuum of amorphous aluminium hydroxyphosphates were formed having properties that changed as a continuous function of the precipitation pH. The phosphate content decreased as the pH of precipitation increased. 27Al NMR spectra revealed that the majority of the aluminium was octahedrally coordinated, with a small percentage of tetrahedrally coordinated aluminium. The density of the adjuvants was directly related to the pH of precipitation. The most prominent feature of the IR and Raman spectra is the P-O stretching vibration of the structural PO(4) groups. The positions of these bands decreased linearly as the precipitation pH increased. The results of selective deuteration FTIR experiments are consistent with high surface area materials as most of the OH groups were exposed near the surface of the adjuvant.

Adjuvants, Immunologic↗

Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part II: physicochemical properties.

The impact of the pH of precipitation on the physicochemical properties of aluminium phosphate adjuvants was investigated by precipitating aluminium phosphate adjuvants under constant pH conditions at pH values from 3.0 to 7.5 at intervals of 0.5. The pH of precipitation did not affect the morphology, but the point of zero charge (PZC) and rate of acid neutralization varied directly with pH of precipitation. Aggregation and protein adsorption capacity exhibited a parabolic relationship to the pH of precipitation. Minimum protein adsorption and maximum aggregation were observed at pH 5.5. In contrast to adjuvants precipitated from the same reactants but under uncontrolled pH conditions, the pH of all of the adjuvants precipitated under constant pH conditions remained constant for a 3-month aging period at room temperature.

Adjuvants, Immunologic↗

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults.

Antigen-specific mucosal immunity is thought to be important for protection against influenza virus infection. Currently licensed parenteral influenza vaccines stimulate the production of serum antibodies, but are poor inducers of mucosal immunity. The adjuvant MF59 has been shown to enhance the humoral immune response to parenteral influenza vaccine in humans and the mucosal immune response to intranasally-administered influenza vaccine in mice. We conducted an open-label safety study followed by an observer-blind, randomized trial comparing the immune response to intranasally-administered subunit influenza vaccine adjuvanted with MF59, unadjuvanted subunit influenza vaccine, and placebo. Adverse reactions did not occur significantly more frequently in vaccinees than placebo recipients. Of 31 subjects receiving 2 doses of MF59-adjuvanted influenza vaccine, 19 (61%), 8 (26%), and 11 (35%) developed a mucosal IgA response to influenza A/H1N1, A/H3N2, and B, respectively. The percentage of subjects with a serum antibody response was slightly lower. The immune responses to adjuvanted vaccine were not significantly different from those to unadjuvanted vaccine. Both vaccines gave more frequent responses than seen in placebo recipients, indicating the potential of intranasal inactivated vaccines to stimulate local IgA responses.

Adjuvants, Immunologic↗